Product
Neoadjuvant Anti-PD-1
1 clinical trial
1 indication
Indication
Esophageal cancerClinical trial
Neoadjuvant PD-1 Blockade (Toripalimab) Monotherapy for Elderly Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: a Phase II TrialStatus: Not yet recruiting, Estimated PCD: 2025-05-01